Great Science
Deep Compassion
Real Impact
Leveraging our long-standing neuroscience
expertise to develop medicines that
make a difference.
Featured News
August 28, 2024
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 22, 2024
Alkermes Announces Initiation of Vibrance-2 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 2
Responsible Growth
Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices.
Inspiring Inclusion
In celebration of International Women's Day, three senior female leaders at Alkermes reflected on their career journeys and their efforts to inspire inclusion.
.png){kind=logo}
United in Purpose
Our employees are the foundation upon which our business is built. Their expertise, intelligence and creativity drive our innovation, and their passion and commitment to excellence are the cornerstone of our success.
R&D Pipeline
We apply our deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. We are currently focused on developing these investigational candidates.
- Discovery
- Preclinical
- Phase 1
- Phase 2
- Phase 3
-
Olanzapine and samidorphan
-
Schizophrenia and Bipolar I Disorder (Pediatric)
Phase 3
OverviewOlanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Clinical TrialsOlanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT05303064.
-
-
ALKS 2680
-
Narcolepsy Type 1
Phase 2
-
Narcolepsy Type 2
Phase 2
OverviewALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy.
Clinical TrialsALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, and Vibrance-2, a phase 2 study in adults with narcolepsy type 2.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:- Vibrance-1: clinicaltrials.gov/study/NCT06358950
- Vibrance-2: clinicaltrials.gov/study/NCT06555783
-
-
Orexin Agonists
-
Neuroscience Indications
Discovery
OverviewAdditional orexin 2 receptor agonists are in discovery for excessive daytime sleepiness disorders and other neuropsychiatric disorders.
-
